Voyxact, an APRIL inhibitor, receives FDA accelerated approval for adults with primary IgA nephropathy to reduce proteinuria.
The FDA approved Itvisma gene therapy for patients aged 2 years and older with spinal muscular atrophy and confirmed SMN1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback